Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group

被引：21

作者：

Aksoylar, Serap ^{[1
]}

Varan, Ali ^{[2
]}

Vergin, Canan ^{[3
]}

Hazar, Volkan ^{[4
]}

Akici, Ferhan ^{[5
]}

Dagdemir, Ayhan ^{[6
]}

Buyukavci, Mustafa ^{[7
]}

Kebudi, Rejin ^{[8
]}

Kurucu, Nilgun ^{[9
]}

Sevinir, Betul ^{[10
]}

Unal, Emel ^{[11
]}

Vural, Sema ^{[12
]}

Guler, Elif ^{[13
]}

Apak, Hilmi ^{[14
]}

Oniz, Haldun ^{[15
]}

Karadeniz, Ceyda ^{[16
]}

Canpolat, Cengiz ^{[17
]}

Anak, Sema ^{[18
]}

Ilhan, Inci ^{[19
]}

Ince, Dilek ^{[20
]}

Cecen, Emre ^{[21
]}

Olgun, Nur ^{[20
]}

机构：

[1] Ege Univ, Fac Med, Dept Pediat Hematol Oncol, Izmir, Turkey

[2] Hacettepe Univ, Fac Med, Dept Pediat Oncol, Ankara, Turkey

[3] Behcet Uz Training & Res Hosp, Dept Pediat Hematol, Izmir, Turkey

[4] Akdeniz Univ, Dept Pediat Oncol, Fac Med, Antalya, Turkey

[5] Kanuni Sultan Suleyman Training & Res Hosp, Dept Pediat Oncol, Istanbul, Turkey

[6] Ondokuz Mayis Univ, Dept Pediat Oncol, Fac Med, Samsun, Turkey

[7] Ataturk Univ, Dept Pediat Oncol, Fac Med, Erzurum, Turkey

[8] Istanbul Univ, Dept Pediat Oncol, Inst Oncol, Istanbul, Turkey

[9] Karadeniz Tech Univ, Dept Pediat Oncol, Fac Med, Trabzon, Turkey

[10] Uludag Univ, Dept Pediat Oncol, Fac Med, Bursa, Turkey

[11] Ankara Univ, Dept Pediat Oncol, Inst Oncol, Ankara, Turkey

[12] Sisli Etfal Training & Res Hosp, Dept Pediat Oncol, Istanbul, Turkey

[13] Gaziantep Univ, Dept Pediat Oncol, Inst Oncol, Gaziantep, Turkey

[14] Istanbul Univ, Dept Pediat Oncol, Cerrahpasa Med Fac, Istanbul, Turkey

[15] Tepecik Training & Res Hosp, Dept Pediat Oncol, Izmir, Turkey

[16] Gazi Univ, Dept Pediat Oncol, Fac Med, Ankara, Turkey

[17] Marmara Univ, Dept Pediat Oncol, Fac Med, Istanbul, Turkey

[18] Istanbul Univ, Dept Pediat Oncol, Fac Med, Istanbul, Turkey

[19] Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Pediat Oncol, Ankara, Turkey

[20] Dokuz Eylul Univ, Dept Pediat Oncol, Inst Oncol, Izmir, Turkey

[21] Adnan Menderes Univ, Dept Pediat Oncol, Fac Med, Aydin, Turkey

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2017年 / 13卷 / 02期

关键词：

Autologous stem cell rescue; high-risk neuroblastoma; treatment; Turkey; STEM-CELL RESCUE; BONE-MARROW-TRANSPLANTATION; MYELOABLATIVE THERAPY; RANDOMIZED-TRIAL; CHEMOTHERAPY; MEGATHERAPY; CLASSIFICATION; EXPERIENCE; CHILDREN; TUMORS;

D O I：

10.4103/0973-1482.183205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The national protocol aimed to improve the outcome of the high risk neuroblastoma patients by high-dose chemotherapy and stem cell rescue with intensive multimodal therapy. Materials and Methods: After the 6 induction chemotherapy cycles, patients without disease progression were nonrandomly (by physicians' and/or parent's choices) allocated into two treatment arms, which were designed to continue the conventional chemotherapy (CCT), or myeloablative therapy with autologous stem cell rescue (ASCR). Results: Fifty-six percent (272 patients) of patients was evaluated as high risk. Response rate to induction chemotherapy was 71%. Overall event-free survival (EFS) and overall survival (OS) at 5 years were 28% and 36%, respectively. "As treated" analysis documented postinduction EFS of 41% in CCT arm (n = 138) and 29% in ASCR group (n = 47) (P = 0.042); whereas, OS was 45% and 39%, respectively (P = 0.05). Thirty-one patients (11%) died of treatment-related complications. Conclusion: Survival rates of high-risk neuroblastoma have improved in Turkey. Myeloablative chemotherapy with ASCR has not augmented the therapeutic end point in our country's circumstances. The adequate supportive care and the higher patients' compliance are attained, the better survival rates might be obtained in high-risk neuroblastoma patients received myeloablative chemotherapy and ASCR.

引用

页码：284 / 290

页数：7

共 27 条

[1] Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial [J].